CapsoVision earnings release, August 13, 2026

CapsoVision, Inc (CV) · Form 8-K, Item 2.02 · Filed · SEC filing

CapsoVision Reports Second Quarter 2026 Financial Results

SARATOGA, Calif., August 13, 2026 - CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided a business update for its second quarter ended June 30, 2026.

Recent Highlights

• Reported second quarter 2026 revenue was $3.6 million, up 10% year over year.

• CapsoCam Plus® used by over 176,000 patients as of June 30, 2026.

• Launched AI Highlights™, the AI-assisted reading feature for CapsoCam Plus®, commercially in the European Union and other international markets to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system.

• Anticipate FDA clearance of AI Highlights™ by the end of the third quarter of 2026, with U.S. commercial launch expected shortly thereafter.

• Continued commercial momentum with expanding adoption across large hospital systems and GI networks, including key customer renewals and growing traction with new customers.

• Pipeline continues to advance with CapsoCam Colon™ on track for 510(k) submission in the fourth quarter of 2026, with ongoing enrollment in the CapsoCam UGI clinical study for pancreatic cancer detection.

• Appointed David S. Shields, M.D., to the Board of Directors, effective July 1, 2026.

• Entered into a sales agreement of up to $100 million providing for an at-the-market equity offering program with Cantor.

Management Commentary

"The second quarter marked another important step in the evolution of CapsoVision as we advanced both our commercial execution and product innovation. We were pleased to launch AI Highlights™ internationally, providing physicians in Europe with an AI-assisted workflow solution that complements our CapsoCam Plus® platform and reinforces our long-term vision of integrated, AI-enabled capsule endoscopy," said Johnny Wang, President and Chief Executive Officer of CapsoVision.

"Commercially, we continue to see encouraging momentum across our business. Revenue growth was in line with our expectations, hospital network adoption continues to expand, and we are adding new customers who recognize the value of our panoramic capsule platform. We also continue to hear strong interest from customers awaiting the U.S. launch of AI Highlights™, which we now anticipate following FDA clearance expected this fall. As we look toward the second half of the year, we remain focused on executing against our commercial strategy while advancing our broader product pipeline."

Second Quarter 2026 Financial Results

Total revenue was $3.6 million compared to $3.3 million in the second quarter of 2025. The primary driver for the revenue growth was a 13% increase in the number of CapsoCam Plus capsules sold offset by a period-over-period decrease of approximately 3% in the average selling price.

Gross profit was 1.9 million, an increase of $0.1 million, or 3% compared to the second quarter of 2025. Gross margin was 51%, compared to 55% in the second quarter of 2025. The decrease was due to a pressure on selling prices we have when operating in a highly competitive market and changes the U.S. government made to the trade policies and tariffs at the beginning of the year resulting in an increase in expenses for customs and tariffs.

Operating expenses were $9.5 million, a $3.0 million increase from the second quarter of 2025, driven primarily by expenses associated with the colon pivotal study and other clinical trials, non-recurring engineering services for the Canon development project, expenses for operating as a public company, and stock-based compensation.

Cash and cash equivalents totaled $9.1 million as of June 30, 2026.

Conference Call and Webcast

CapsoVision will host a conference call today, August 13, 2026, at 4:30 p.m. ET to discuss its second quarter financial results. Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conference ID 9178774, or from the webcast link on the Events page in the investor relations section of the company's website at www.capsovision.com.

To access the replay, please register via the webcast link on the Events page. The webcast will be available for one year following the completion of the call.

About CapsoVision

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.

Financial statements

Income Statement

Three Months Ended June 30, — (in thousands, except share and per-share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net revenue3,6433,3156,4356,098
Costs of revenue1,7721,5043,2352,793
Gross profit1,8711,8113,2003,305
OPERATING EXPENSESSelling and marketing1,9361,8474,0273,808
OPERATING EXPENSESResearch and development5,3093,3929,7446,499
OPERATING EXPENSESGeneral and administrative2,2061,2234,1023,031
OPERATING EXPENSESTotal operating expenses9,4516,46217,87313,338
OPERATING EXPENSESOperating loss-7,580-4,651-14,673-10,033
NON-OPERATING INCOMEInterest income, net823714143
NON-OPERATING INCOMEOther non-operating income (expense), net17-1118-10
NON-OPERATING INCOMETotal non-operating income, net992615933
NON-OPERATING INCOMELoss before income taxes-7,481-4,625-14,514-10,000
NON-OPERATING INCOMENet loss and comprehensive loss-7,481-4,625-14,514-10,000
NON-OPERATING INCOMENet loss per share – basic and diluted-0.15-2.02-0.3-4.49
NON-OPERATING INCOMEWeighted average common shares outstanding – basic and diluted49,937,5252,292,23048,704,0692,225,301

Balance Sheet

June 30, 2026 — (in thousands, except par value and share amounts)

June 30, 2026December 31, 2025
Current AssetsCash and cash equivalents9,07710,112
Current AssetsAccounts receivable, net2,2652,498
Current AssetsInventory4,7042,987
Current AssetsPrepaid expenses and other current assets1,2341,072
Current AssetsTotal current assets17,28016,669
Current AssetsProperty and equipment, net562611
Current AssetsOperating lease right-of-use assets651843
Current AssetsOther long-term assets7641
Current AssetsTOTAL ASSETS18,56918,164
Current LiabilitiesAccounts payable4751,143
Current LiabilitiesAccrued expenses and other current liabilities4,1012,697
Current LiabilitiesDeferred revenue140177
Current LiabilitiesOperating lease liabilities – current442410
Current LiabilitiesTotal current liabilities5,1584,427
Current LiabilitiesOperating lease liabilities – long-term245477
Current LiabilitiesTotal liabilities5,4034,904

Balance Sheet

(in thousands, except par value and share amounts)

Stockholders’ EquityCommon stock, $0.001 par value: 300,000,000 shares authorized as of June 30, 2026; 50,032,148 and 46,865,051 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively5047
Stockholders’ EquityAdditional paid-in capital183,295168,878
Stockholders’ EquityAccumulated deficit-170,179-155,665
Stockholders’ EquityTotal stockholders’ equity13,16613,260
Stockholders’ EquityTOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY18,56918,164

Cash Flow

Six Months Ended June 30, — (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIESNet loss-14,514-10,000
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization114107
Adjustments to reconcile net loss to net cash used in operating activities:Amortization of operating lease right-of-use assets192171
Adjustments to reconcile net loss to net cash used in operating activities:Unrealized foreign exchange losses (gains)15-158
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation911322
Adjustments to reconcile net loss to net cash used in operating activities:Bad debt expense11
Changes in operating assets and liabilities:Accounts receivable245167
Changes in operating assets and liabilities:Inventory-1,717-413
Changes in operating assets and liabilities:Prepaid expenses and other current assets-162-939
Changes in operating assets and liabilities:Other long-term assets-35
Changes in operating assets and liabilities:Accounts payable-685408
Changes in operating assets and liabilities:Accrued expenses and other current liabilities1,4041,019
Changes in operating assets and liabilities:Deferred revenue-37-35
Changes in operating assets and liabilities:Operating lease liabilities-200-172
Changes in operating assets and liabilities:Net cash used in operating activities-14,469-9,512
CASH FLOWS FROM INVESTING ACTIVITIESPurchases of property and equipment-48-70
CASH FLOWS FROM INVESTING ACTIVITIESNet cash used in investing activities-48-70
CASH FLOWS FROM FINANCING ACTIVITIESProceeds from promissory note issuance1,000
CASH FLOWS FROM FINANCING ACTIVITIESProceeds from Private Placement14,000
CASH FLOWS FROM FINANCING ACTIVITIESPayment of Private Placement issuance costs-600
CASH FLOWS FROM FINANCING ACTIVITIESPayment of constructive dividend-12
CASH FLOWS FROM FINANCING ACTIVITIESProceeds from exercises of options on common stock and warrants121202
CASH FLOWS FROM FINANCING ACTIVITIESNet cash provided by financing activities13,5091,202
CASH FLOWS FROM FINANCING ACTIVITIESNet decrease in cash and cash equivalents-1,008-8,380
CASH FLOWS FROM FINANCING ACTIVITIESEffect of exchange rate changes on cash and cash equivalents-27127
CASH FLOWS FROM FINANCING ACTIVITIESCash and cash equivalents at beginning of period10,1129,319
CASH FLOWS FROM FINANCING ACTIVITIESCash and cash equivalents at end of period9,0771,066
SUPPLEMENTAL CASH FLOW DISCLOSURESCash paid for income taxes117
Full release

Forward-Looking Statements... (truncated)f operations and financial position, including the Company’s expectations regarding the Company’s product and clinical development efforts, the timing and receipt of regulatory submissions and approvals , the Company’s plans, strategies and timing for its pipeline development (including the anticipated timing of FDA clearance of AI Highlights™ and its subsequent U.S. commercial launch, the continued development and anticipated 510(k) submission for CapsoCam Colon™, and the clinical study for CapsoCam® UGI in pancreatic cancer detection) and the success of the Company’s plans and strategies. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties, including those beyond the Company’s control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions (including competition in the capsule endoscopy market), the Company’s financial condition and the availability of cash and financing (including through the Company’s at-the-market equity offering program), the success of the Company’s product and clinical development efforts, the failure to receive regulatory clearance or approval, changes in U.S. trade policies, tariffs or other government regulations that could increase the Company’s costs or affect the Company’s supply chain, and the failure to adapt the Company’s products for new indications. These and other risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s most recent Form 10-K and Form 10-Q. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as required by law.

Investor Relations Contact

Leigh Salvo

New Street Investor Relations

Investors@CapsoVision.com

Media Contact

Leslie Strickler and Paul Spicer

Être Communications leslies@etrecommunications.com

(804) 240-0807

pauls@etrecommunications.com

(804) 503-9231

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · CapsoVision earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.